IDEAYA is dedicated to pioneering oncology treatments through innovative clinical trials. Through rigorous scientific inquiry and unwavering dedication, we strive to bring new hope to cancer patients and contribute to the advancement of oncology treatment paradigms. Our clinical trials page offers a comprehensive overview of our ongoing studies which span various solid tumor cancer types, with a focus on biomarker-driven approaches.
Darovasertib
PKC
Darovasertib PKC
IDE196-002
Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator’s choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Recruiting
18 Years and older (Adult, Older Adult)
All Sexes
NCT ID: 5987332
IDE196-001
Patients with Solid Tumors Harboring GNAQ/11 Mutations
Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations, including metastatic uveal melanoma (MUM) and cutaneous melanoma
Recruiting
18 Years and older (Adult, Older Adult)
All Sexes
NCT ID: 03947385
IDE196-009
Uveal Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Recruiting
18 Years and older (Adult, Older Adult)
All Sexes
NCT ID: 05907954
IDE397
MAT2A
IDE397 / MAT2A
IDE397-001
Solid Tumors Harboring MTAP Deletion
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and anti-tumor activity of IDE397 as a single agent and in combination with docetaxel or paclitaxel, or sacituzumab govitecan-hziyin (SG) in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy or for whom no curative therapy is available. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Recruiting
18 Years and older (Adult, Older Adult)
All Sexes
NCT ID: 04794699
IDE161
PARG
IDE161 / PARG
IDE161-001
Patients with HRD Mutations
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.
Recruiting
18 Years and older (Adult, Older Adult)
All Sexes
NCT ID: 05787587
Disclaimer: This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.
Expanded Access Policy
Investigational drugs are medical products that have not yet been approved or cleared by FDA and the FDA has not found these drug products to be safe and effective for their specific use. Investigational drug products may, or may not, be effective in the treatment of the condition for which they are being investigated, and use of the product may cause unexpected serious side effects.
Currently, participation in a clinical trial is the only way to receive any of IDEAYA’s investigational drugs. Until further safety and efficacy data become available, we will not be making these investigational drugs available in other ways. If you have questions about participating in a clinical trial, please speak to your treating physician or contact IDEAYAClinicalTrials@ideayabio.com.
Contact Us About a Trial
Complete the Form to Inquire About Clinical Trials
Fill out my online form.
CONTACT US
5000 Shoreline Court, Suite 300
South San Francisco, CA 94080
11710 El Camino Real
San Diego, CA 92130
